Cyclacel Pharmaceuticals Files 8-K with Key Corporate Updates
Ticker: BGMSP · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
Related Tickers: CYCC
TL;DR
Cyclacel dropped an 8-K detailing material agreements, equity sales, and changes to shareholder rights.
AI Summary
On March 21, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing several significant events. These include entering into a material definitive agreement, unregistered sales of equity securities, and material modifications to the rights of security holders. The company also reported amendments to its articles of incorporation or bylaws and other events.
Why It Matters
This filing indicates significant corporate actions and potential changes in the rights of Cyclacel's security holders, which could impact investors.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities and material modifications to security holder rights, which can introduce uncertainty and risk.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- March 21, 2025 (date) — Date of earliest event reported
- 200 CONNELL DRIVE (address) — Business and Mail Address
- BERKELEY HEIGHTS (city) — Business and Mail City
- NJ (state) — Business and Mail State
- 07922 (zip_code) — Business and Mail Zip Code
FAQ
What is the nature of the material definitive agreement entered into by Cyclacel Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What type of equity securities were sold in the unregistered sale?
The filing does not specify the type of equity securities involved in the unregistered sale.
What are the material modifications to the rights of security holders?
The filing lists this as an event but does not provide specific details on the modifications.
When was Cyclacel Pharmaceuticals, Inc. formerly known as XCYTE THERAPIES INC?
The date of the name change from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. was December 18, 2000.
What is the SIC code for Cyclacel Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Cyclacel Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).